Explore 11-year findings on diabetes remission after bariatric surgery, including who benefits most, why relapse occurs, and what patients should know.
Read More »Less Insulin, More Weight Loss? A New Type 1 Diabetes Drug Shows Early Promise
Phase 2 acmopatide results in type 1 diabetes show promising weight loss and reduced insulin use. Explore A1C findings, safety, and limitations.
Read More »Retatrutide vs. Ozempic: What the 80-Week Head-to-Head Diabetes Trial Revealed
See how retatrutide compared with Ozempic 2 mg in an 80-week Phase 3 diabetes trial, including A1C reduction, weight loss, and side effects.
Read More »Lose 5% Now, Benefit Decades Later? Prediabetes Data Point to a Possible Legacy Effect
A 34-year study links early weight loss in prediabetes to lower cardiovascular risks. Explore the findings and what they mean for prevention.
Read More »Type 1 Diabetes Care Just Changed: The 2026 ADA/EASD Update Clinicians Need to Know
The type 1 diabetes consensus 2026 expands guidance on AID, cardiovascular risk, obesity, complications, psychosocial care, and new therapies.
Read More »Can Weight Loss Delay Type 1 Diabetes? What the Pre-Symptomatic Data Really Show
Efforts to prevent or delay type 1 diabetes have traditionally focused on the autoimmune attack that destroys insulin-producing beta cells. However, emerging research suggests metabolic stress may also influence how quickly vulnerable people progress to clinical disease. A 2026 TrialNet analysis found that autoantibody-positive people with overweight or obesity who …
Read More »Amylin Is Making a Comeback: Why This Forgotten Hormone Is Back in the Spotlight
For years, glucagon-like peptide-1 (GLP-1) receptor agonists have dominated conversations about diabetes and obesity treatment. However, another hormone is quietly returning to the spotlight. Amylin diabetes therapy is making a comeback as researchers develop a new generation of drugs designed to improve blood glucose control and support weight management. Amylin …
Read More »The Glucagon Paradox: Why Activating a “Blood Sugar Hormone” Can Improve Metabolic Health
For decades, glucagon has been viewed as insulin’s opposite. While insulin lowers blood glucose, glucagon raises it by signaling the liver to release stored sugar into the bloodstream. Because of this, glucagon has traditionally been considered a hormone to suppress in people living with type 2 diabetes. However, modern research …
Read More »When Weight Loss Isn’t the Whole Story: Managing Binge Eating Disorder in Type 2 Diabetes
For many people living with binge eating disorder and type 2 diabetes, managing blood sugar isn’t just about counting carbohydrates or losing weight. Emotional eating, loss of control around food, and feelings of guilt can quietly interfere with diabetes care, even when someone is taking the right medications. Because of …
Read More »Your Patient Is Taking a Compounded GLP-1. Now What?
As demand for GLP-1 receptor agonists continues to outpace supply, many patients have turned to compounded medications obtained through telehealth companies, medical spas, wellness clinics, and compounding pharmacies. While these products may improve access for some individuals, they also introduce important clinical, regulatory, and medicolegal challenges. Providers increasingly encounter patients …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.